1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: A Negative Control for Src Kinase Inhibitor PP 2

Executive Summary: 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS 5334-30-5) is a chemically defined, DMSO-soluble small molecule used as a negative control for Src kinase inhibitor PP 2, critical for Src kinase signaling pathway research and protein tyrosine kinase inhibition studies (APExBIO). Its use enhances experimental rigor by distinguishing specific from off-target kinase effects (AY-9944.com). Recent studies emphasize its role in signal transduction analyses, including vascular contraction models mediated by NADPH oxidase-derived ROS (Shvetsova et al., 2025). The compound is supplied at ≥98% purity with comprehensive documentation (COA, MSDS). It is strictly for research use only; diagnostic or medical application is neither intended nor permitted.

Biological Rationale

Protein tyrosine kinases, notably the Src family, are pivotal in regulating cellular signaling pathways relevant to proliferation, migration, and vascular tone. Aberrant Src kinase activity is implicated in oncogenic transformation and vascular dysfunction (Shvetsova et al., 2025). Selective inhibition of Src kinases enables mechanistic dissection of these pathways. However, specific attribution of observed effects to Src kinase inhibition requires robust negative controls to rule out non-specific or off-target phenomena.

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine lacks Src inhibitory activity but is structurally analogous to PP 2, making it a stringent negative control in kinase signaling pathway research (APExBIO). This utility extends across cell signaling, cancer biology, and vascular physiology studies where precise modulation of kinase activity is essential.

Mechanism of Action of 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

PP 2 is a potent inhibitor of Src family kinases, acting via competitive binding at the ATP site. 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (SKU B7190), while structurally similar, does not inhibit Src kinases at relevant concentrations (typically 10 μM) (Shvetsova et al., 2025). This functional inactivity enables it to serve as a benchmark for distinguishing specific Src kinase-driven effects from chemical, solubility, or vehicle-related artifacts.

When used in parallel with PP 2, any differences in biological outcome can be attributed to Src kinase inhibition, provided all other variables are controlled. This negative control approach is critical in signal transduction studies, especially in complex systems involving cross-talk between ROS, calcium channels, and kinase pathways as elucidated in vascular contraction models (Shvetsova et al., 2025).

Evidence & Benchmarks

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine does not inhibit Src kinase activity at 10 μM, while PP 2 produces significant inhibition under identical conditions (Shvetsova et al., 2025).
• In saphenous artery contraction assays, only PP 2—but not the negative control—reduces NADPH oxidase-mediated contractile responses in early postnatal rats (Shvetsova et al., 2025).
• APExBIO supplies SKU B7190 with a molecular weight of 211.22 g/mol, purity ≥98%, and solubility in DMSO (>10 mg/mL), validated by Certificate of Analysis (APExBIO).
• Parallel assays using PP 2 and its negative control are recommended to control for vehicle and off-target effects in kinase pathway studies (Ovalbumin-324-338.com).
• The negative control does not alter L-type Ca²⁺ channel activity or basal ROS production in vascular tissue (Shvetsova et al., 2025).

This article extends the mechanistic insights provided in '1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine in Src Kinase Inhibitor Studies' by integrating direct evidence from recent ROS-mediated vascular contraction research. For advanced assay design strategies, see 'Enhancing Assay Specificity', which this article updates with stricter control benchmarks.

Applications, Limits & Misconceptions

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is established as a reference negative control in Src kinase signaling pathway research. Applications include:

• Dissecting kinase-dependent vs. independent effects in cellular and tissue-based assays.
• Improving the specificity and reproducibility of high-throughput kinase inhibitor screens.
• Clarifying the mechanistic involvement of Src kinases in vascular contraction, cancer cell proliferation, and signal transduction (PS-341.com).

However, it is not suitable for use as a positive control or as a Src kinase inhibitor itself. The compound is strictly intended for research use and not for therapeutic or diagnostic purposes. Misapplication may lead to erroneous attribution of biological effects.

Common Pitfalls or Misconceptions

• Assuming 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine inhibits Src kinases—it does not; it serves solely as a negative control (Shvetsova et al., 2025).
• Using the compound for diagnostic, therapeutic, or in vivo clinical applications is not permitted (APExBIO product documentation).
• Storing prepared solutions for extended periods—fresh use is recommended due to stability limits (APExBIO).
• Confusing structural similarity with functional equivalence—structural analogs may lack biological activity.
• Overlooking the need for documentation (COA, MSDS) to ensure batch-specific reproducibility.

Workflow Integration & Parameters

SKU B7190 from APExBIO is supplied as a white to off-white solid, with a molecular formula of C₁₁H₉N₅ and a molecular weight of 211.22 g/mol. It is soluble in DMSO at concentrations exceeding 10 mg/mL. Store at −20°C for optimal stability; ship with blue ice. Solutions should be freshly prepared and used promptly.

For kinase assay workflows, parallel use of PP 2 and its negative control is recommended at matched concentrations (typically 10 μM), with vehicle controls included. Rigorous documentation (COA/MSDS) accompanies each lot. See the B7190 kit for detailed parameters and handling recommendations.

Conclusion & Outlook

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a gold-standard negative control for Src kinase inhibitor PP 2, enabling precise attribution of kinase-dependent phenomena in research settings. Its defined properties, validated inactivity, and integration into modern assay workflows support reproducibility and scientific rigor. Future work may extend its use to broader kinase panel studies and emerging models of cell signaling and vascular biology.